News
Spero Therapeutics, Inc. (NASDAQ: SPRO) Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats ...
The ADC market is rapidly advancing due to next-gen oncology therapeutics and increased R&D, offering significant opportunities for addressing treatment-resistant cancersDublin, Aug. 13, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback